Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

However, the currently available evaluation tools predict only the outcome of amino-acid exchanges and cannot ... that might affect the amount of mRNA. Test results are then evaluated by a naive ...

Proteins are the building blocks of life. They consist of folded peptide chains, which in turn are made up of a series of ...

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

South Korean researchers have, for the first time in the world, uncovered how messenger ribonucleic acid (mRNA) vaccines ...

How chromatin openness controls behavioral changes remains unclear. This work implicates alternative promoter selection, ...

The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the year. More recently, the conspicuous ...

The working principle of the ribonucleic acid (mRNA) vaccine, which played a role of 'relief pitcher' during the COVID-19 pandemic, has been revealed by a domestic research team. A research team led ...

Immunizing mice with an edited Lyme disease-causing bacterial protein effectively protected them against the disease.

Shihabeddin et al utilized single-cell RNA-Seq analysis of adult P23H zebrafish animals to identify transcription factors (e2fs, Prdm1a, Sp1) expressed selectively in neural progenitors and immature ...

Learn more about whether Moderna, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.